Skytrofa 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0022 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
31/10/2023 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
IB/0021 
B.I.a.3.a - Change in batch size (including batch size 
18/10/2023 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
PSUSA/10969
Periodic Safety Update EU Single assessment - 
28/09/2023 
n/a 
PRAC Recommendation - maintenance 
/202302 
lonapegsomatropin 
IA/0020 
B.I.b.2.a - Change in test procedure for AS or 
19/09/2023 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IA/0017 
A.7 - Administrative change - Deletion of 
12/05/2023 
n/a 
manufacturing sites 
IB/0016 
B.I.a.2.z - Changes in the manufacturing process of 
28/04/2023 
n/a 
the AS - Other variation 
IB/0014 
C.I.11.z - Introduction of, or change(s) to, the 
11/04/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/10969
Periodic Safety Update EU Single assessment - 
16/03/2023 
n/a 
PRAC Recommendation - maintenance 
/202208 
lonapegsomatropin 
IB/0012 
B.I.c.1.c - Change in immediate packaging of the AS 
20/02/2023 
n/a 
- Liquid ASs (non sterile) 
IAIN/0015/G 
This was an application for a group of variations. 
17/02/2023 
n/a 
A.7 - Administrative change - Deletion of 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0013 
B.IV.1.a.1 - Change of a measuring or administration 
25/01/2023 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
SmPC, 
Labelling and 
PL 
IB/0011 
B.I.d.1.z - Stability of AS - Change in the re-test 
20/12/2022 
n/a 
period/storage period or storage conditions - Other 
variation 
PSUSA/10969
Periodic Safety Update EU Single assessment - 
13/10/2022 
20/12/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202202 
lonapegsomatropin 
the variation to terms of the Marketing Authorisation(s) for 
PSUSA/00010969/202202 
IB/0009 
B.I.a.3.a - Change in batch size (including batch size 
24/10/2022 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IB/0007 
B.I.a.1.z - Change in the manufacturer of AS or of a 
05/10/2022 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IA/0008 
A.5.b - Administrative change - Change in the name 
14/09/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0006/G 
This was an application for a group of variations. 
24/08/2022 
20/12/2022 
SmPC, 
Labelling and 
PL 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.2.a - Administrative change - Change in the 
(invented) name of the medicinal product for CAPs 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
IB/0004 
B.I.b.2.a - Change in test procedure for AS or 
22/07/2022 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0005 
B.II.d.2.a - Change in test procedure for the finished 
21/07/2022 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0003 
B.I.b.2.e - Change in test procedure for AS or 
27/06/2022 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0002 
B.I.a.2.a - Changes in the manufacturing process of 
07/06/2022 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
